Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail

  1. Brandon R Lowe
  2. Rajesh K Yadav
  3. Ryan A Henry
  4. Patrick Schreiner
  5. Atsushi Matsuda
  6. Alfonso G Fernandez
  7. David Finkelstein
  8. Margaret Campbell
  9. Satish Kallappagoudar
  10. Carolyn M Jablonowski
  11. Andrew J Andrews
  12. Yasushi Hiraoka
  13. Janet F Partridge  Is a corresponding author
  1. St Jude Children's Research Hospital, United States
  2. Fox Chase Cancer Center, United States
  3. National Institute of Information and Communications Technology, Japan
  4. Osaka University, Japan

Abstract

Sequencing of cancer genomes has identified recurrent somatic mutations in histones, termed oncohistones, which are frequently poorly understood. Previously we showed that fission yeast expressing only the H3.3G34R mutant identified in aggressive pediatric glioma had reduced H3K36 trimethylation and acetylation, increased genomic instability and replicative stress, and defective homology-dependent DNA damage repair (Yadav et al., 2017). Here we show that surprisingly distinct phenotypes result from G34V (also in glioma) and G34W (giant cell tumors of bone) mutations, differentially affecting H3K36 modifications, subtelomeric silencing, genomic stability, sensitivity to irradiation, alkylating agents, hydroxyurea and influencing DNA repair. In cancer, only one of thirty alleles encoding H3 is mutated. Whilst co-expression of wild-type H3 rescues most G34 mutant phenotypes, G34R causes dominant hydroxyurea sensitivity and homologous recombination defects, and dominant subtelomeric silencing. Together, these studies demonstrate the complexity associated with different substitutions at even a single residue in H3 and highlight the utility of genetically tractable systems for their analysis.

Data availability

RNAseq data have been deposited in GEO under accession code GSE162572.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Brandon R Lowe

    Department of Pathology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Rajesh K Yadav

    Pathology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Ryan A Henry

    Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Patrick Schreiner

    Center for Applied Bioinformatics, Dept. of Bioinformatics, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5391-2642
  5. Atsushi Matsuda

    Advanced ICT Research Institute, National Institute of Information and Communications Technology, Kobe, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0510-213X
  6. Alfonso G Fernandez

    Pathology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. David Finkelstein

    Computational Biology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Margaret Campbell

    Pathology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Satish Kallappagoudar

    Pathology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Carolyn M Jablonowski

    Pathology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Andrew J Andrews

    Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Yasushi Hiraoka

    Graduate School of Frontier Biosciences, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9407-8228
  13. Janet F Partridge

    Pathology, St Jude Children's Research Hospital, Memphis, United States
    For correspondence
    janet.partridge@stjude.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1102-6305

Funding

St. Baldrick's Foundation (Research grant with generous support from the Henry Cermak fund for Pediatric Cancer Research.)

  • Janet F Partridge

National Cancer Institute (Cancer Center support grant (NCI CCSG 2 P30 CA21765))

  • Rajesh K Yadav
  • Janet F Partridge

American Lebanese Syrian Associated Charities

  • Brandon R Lowe
  • Rajesh K Yadav
  • Patrick Schreiner
  • Alfonso G Fernandez
  • David Finkelstein
  • Margaret Campbell
  • Satish Kallappagoudar
  • Carolyn M Jablonowski
  • Janet F Partridge

National Institutes of Health (NIH GM102503)

  • Andrew J Andrews

Fox Chase Cancer Center (Board of Associates Fellowship)

  • Ryan A Henry

Japan Society for the Promotion of Science (Kakheni grant JP19H03202 and JP20H05894)

  • Atsushi Matsuda

Japan Society for the Promotion of Science (Kakheni grants JP18H05533 and JP20H00454)

  • Yasushi Hiraoka

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jerry L Workman, Stowers Institute for Medical Research, United States

Publication history

  1. Received: December 2, 2020
  2. Accepted: January 30, 2021
  3. Accepted Manuscript published: February 1, 2021 (version 1)
  4. Version of Record published: February 9, 2021 (version 2)

Copyright

© 2021, Lowe et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,214
    Page views
  • 219
    Downloads
  • 6
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Brandon R Lowe
  2. Rajesh K Yadav
  3. Ryan A Henry
  4. Patrick Schreiner
  5. Atsushi Matsuda
  6. Alfonso G Fernandez
  7. David Finkelstein
  8. Margaret Campbell
  9. Satish Kallappagoudar
  10. Carolyn M Jablonowski
  11. Andrew J Andrews
  12. Yasushi Hiraoka
  13. Janet F Partridge
(2021)
Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail
eLife 10:e65369.
https://doi.org/10.7554/eLife.65369

Further reading

    1. Chromosomes and Gene Expression
    2. Developmental Biology
    Lewis Macdonald et al.
    Tools and Resources

    Auxin-inducible degrons are a chemical genetic tool for targeted protein degradation and are widely used to study protein function in cultured mammalian cells. Here we develop CRISPR-engineered mouse lines that enable rapid and highly specific degradation of tagged endogenous proteins in vivo. Most but not all cell types are competent for degradation. By combining ligand titrations with genetic crosses to generate animals with different allelic combinations, we show that degradation kinetics depend upon the dose of the tagged protein, ligand, and the E3 ligase substrate receptor TIR1. Rapid degradation of condensin I and condensin II - two essential regulators of mitotic chromosome structure - revealed that both complexes are individually required for cell division in precursor lymphocytes, but not in their differentiated peripheral lymphocyte derivatives. This generalisable approach provides unprecedented temporal control over the dose of endogenous proteins in mouse models, with implications for studying essential biological pathways and modelling drug activity in mammalian tissues.

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Jakub Gemperle et al.
    Tools and Resources

    CRISPR technology has made generation of gene knock-outs widely achievable in cells. However, once inactivated, their re-activation remains difficult, especially in diploid cells. Here, we present DExCon (Doxycycline-mediated endogenous gene Expression Control), DExogron (DExCon combined with auxin-mediated targeted protein degradation), and LUXon (light responsive DExCon) approaches which combine one-step CRISPR-Cas9-mediated targeted knockin of fluorescent proteins with an advanced Tet-inducible TRE3GS promoter. These approaches combine blockade of active gene expression with the ability to re-activate expression on demand, including activation of silenced genes. Systematic control can be exerted using doxycycline or spatiotemporally by light, and we demonstrate functional knock-out/rescue in the closely related Rab11 family of vesicle trafficking regulators. Fluorescent protein knock-in results in bright signals compatible with low-light live microscopy from monoallelic modification, the potential to simultaneously image different alleles of the same gene, and bypasses the need to work with clones. Protein levels are easily tunable to correspond with endogenous expression through cell sorting (DExCon), timing of light illumination (LUXon), or by exposing cells to different levels of auxin (DExogron). Furthermore, our approach allowed us to quantify previously unforeseen differences in vesicle dynamics, transferrin receptor recycling, expression kinetics, and protein stability among highly similar endogenous Rab11 family members and their colocalization in triple knock-in ovarian cancer cell lines.